Literature DB >> 17462974

Yeast on drugs: Saccharomyces cerevisiae as a tool for anticancer drug research.

M Menacho-Márquez1, J R Murguía.   

Abstract

The budding yeast Saccharomyces cerevisiae is being widely used as a model for investigating fundamental processes relevant to all living organisms. Many of these processes are affected by genetic and epigenetic alterations in cancer such as cell cycle progression, DNA replication and segregation, maintenance of genomic integrity and stress responses. Therefore, yeast emerges as an attractive model for anticancer drug research. The genetic tractability of budding yeast, its ease of manipulation and the wealth of functional genomics tools available in this organism makes it ideal for genome-wide analysis of biological functions and chemical screenings. The present review will discuss some of the innovative advantages based on yeast genetics and genomics for antitumour drug target identification and drug discovery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462974     DOI: 10.1007/s12094-007-0043-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  19 in total

1.  Quantitative- and phospho-proteomic analysis of the yeast response to the tyrosine kinase inhibitor imatinib to pharmacoproteomics-guided drug line extension.

Authors:  Sandra C Dos Santos; Nuno P Mira; Ana S Moreira; Isabel Sá-Correia
Journal:  OMICS       Date:  2012-07-09

2.  Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro.

Authors:  Alethia A Hostetter; Michelle L Miranda; Victoria J DeRose; Karen L McFarlane Holman
Journal:  J Biol Inorg Chem       Date:  2011-07-08       Impact factor: 3.358

3.  Confirmation of the cellular targets of benomyl and rapamycin using next-generation sequencing of resistant mutants in S. cerevisiae.

Authors:  Dustin A Wride; Nader Pourmand; Walter M Bray; Jacob J Kosarchuk; Sean C Nisam; Tiffani K Quan; Ray F Berkeley; Sol Katzman; Grant A Hartzog; Carlos E Dobkin; R Scott Lokey
Journal:  Mol Biosyst       Date:  2014-12

Review 4.  Progress in metabolic engineering of Saccharomyces cerevisiae.

Authors:  Elke Nevoigt
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

5.  A model for the spatiotemporal organization of DNA replication in Saccharomyces cerevisiae.

Authors:  T W Spiesser; E Klipp; Matteo Barberis
Journal:  Mol Genet Genomics       Date:  2009-03-22       Impact factor: 3.291

6.  Yeast toxicogenomics: genome-wide responses to chemical stresses with impact in environmental health, pharmacology, and biotechnology.

Authors:  Sandra C Dos Santos; Miguel Cacho Teixeira; Tânia R Cabrito; Isabel Sá-Correia
Journal:  Front Genet       Date:  2012-04-19       Impact factor: 4.599

7.  The effect of bioactive compounds on in vitro and in vivo antioxidant activity of different berry juices.

Authors:  Ana Slatnar; Jerneja Jakopic; Franci Stampar; Robert Veberic; Polona Jamnik
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

8.  Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis.

Authors:  David Quinto-Alemany; Ana Canerina-Amaro; Luís G Hernández-Abad; Félix Machín; Floyd E Romesberg; Cristina Gil-Lamaignere
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

9.  Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members.

Authors:  T E Beaumont; T M Shekhar; L Kaur; D Pantaki-Eimany; M Kvansakul; C J Hawkins
Journal:  Cell Death Dis       Date:  2013-05-02       Impact factor: 8.469

10.  Targeting Cdc42 with the anticancer compound MBQ-167 inhibits cell polarity and growth in the budding yeast S. cerevisiae.

Authors:  Michael John Rivera-Robles; Julia Medina-Velázquez; Gabriela M Asencio-Torres; Sahily González-Crespo; Brian C Rymond; José Rodríguez-Medina; Suranganie Dharmawardhane
Journal:  Small GTPases       Date:  2018-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.